Glucagon-like peptide 1 (GLP1)-based Therapies
Market
Glucagon-like peptide 1 (GLP-1)-based Therapies
Market Scope: Industry Analysis, Market Size,
Growth, Trends Till 2031
Request Sample Report
Glucagon-like peptide 1 (GLP-1)-based Therapies
Market Size and Growth
The Global Glucagon-like peptide 1 (GLP-1)-based Therapies market is expected to experience significant growth due to increasing prevalence of diabetes and obesity. The market size is projected to reach $10.5 billion by 2025, with a CAGR of 8.3%. Factors such as advancements in technology and rising demand for effective treatment options are driving market expansion. Request Sample Report
Companies Covered
(Covid 19 Impact Covered)
◍ Novo Nordisk
◍ AstraZeneca
◍ Eli Lily
◍ GSK
◍ Sanofi
◍ Bristol-Myers Squibb
The competitive landscape of GLP-1-based therapies market includes Novo Nordisk, AstraZeneca, Eli Lily, GSK, Sanofi, and Bristol-Myers Squibb. These companies develop and market GLP-1-based treatments for diabetes and obesity. They increase market growth by investing in research, marketing, and partnerships.
- Novo Nordisk: $18.72 billion
- AstraZeneca: $24.39 billion
- Sanofi: $37.67 billion
Request Sample Report
Market Segmentation
By Application
Hospital
Pharmacy Request Sample Report
By Product
Exenatied
Liraglutide
Lixisenatide
Albiglutide
Dulaglutide
◍
◍
◍
◍
◍
◍
◍
Market Growth
Request Sample Report
$ X Billion USD
THANK YOU Email : sales@reportprime.com USA : +1 507 500 7209 Website : https://www.reportprime.com/ Request Sample Report Contact US Our Clients